A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CB2 / cannabinoid type 2

[Related PubMed/MEDLINE]
Total Number of Papers: 54
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CB2  (>> Co-occurring Abbreviation)
Long Form:   cannabinoid type 2
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A cannabinoid type 2 (CB2) receptor agonist augments NOS-dependent responses of cerebral arterioles during type 1 diabetes. T1D
2020 Cannabinoid type 2 receptor agonist JWH133 decreases blood pressure of spontaneously hypertensive rats through relieving inflammation in the rostral ventrolateral medulla of the brain. AAV, BP, HR, RSNA, RVLM, SHRs, WKY
2020 CB2 Receptors and Neuron-Glia Interactions Modulate Neurotoxicity Generated by MAGL Inhibition. CB1, MAGL
2020 Lenabasum for Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. ACR, CB, CRISS, dcSSc
2020 The ameliorating effect of cannabinoid type 2 receptor activation on brain, lung, liver and heart damage in cecal ligation and puncture-induced sepsis model in rats. CLP
2019 2-Linoleoylglycerol Is a Partial Agonist of the Human Cannabinoid Type 1 Receptor that Can Suppress 2-Arachidonolyglycerol and Anandamide Activity. 2-AG, 2-LG, AEA, CB1, eCB
2019 Activation of cannabinoid type 2 receptor protects skeletal muscle from ischemia-reperfusion injury partly via Nrf2 signaling. Nrf2
2019 Amelioration of visual deficits and visual system pathology after mild TBI with the cannabinoid type-2 receptor inverse agonist SMM-189. ---
2019 beta-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain. BCP, CB1, HIV, NRTIs
10  2019 beta-Caryophyllene, a natural bicyclic sesquiterpene attenuates doxorubicin-induced chronic cardiotoxicity via activation of myocardial cannabinoid type-2 (CB2) receptors in rats. BCP, DOX, NF-kappaB
11  2019 Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats. BDNF, IL, P2X4
12  2019 Palmitoylethanolamide counteracts substance P-induced mast cell activation in vitro by stimulating diacylglycerol lipase activity. 2-AG, DAGL, PEA, SP, TRPV1
13  2019 Structure-Activity Relationship Studies of Pyridine-Based Ligands and Identification of a Fluorinated Derivative for Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. PET
14  2019 Synthesis of novel 2-(1-adamantanylcarboxamido)thiophene derivatives. Selective cannabinoid type 2 (CB2) receptor agonists as potential agents for the treatment of skin inflammatory disease. ---
15  2019 Tempering aversive/traumatic memories with cannabinoids: a review of evidence from animal and human studies. CB1, eCB, PTSD
16  2019 The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases. CB1
17  2019 The protective effect of cannabinoid type 2 receptor activation on renal ischemia-reperfusion injury. IR
18  2018 Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment. ---
19  2018 An overview of the cannabinoid type 2 receptor system and its therapeutic potential. ---
20  2018 Anti-inflammatory Properties of Cannabidiol, a Nonpsychotropic Cannabinoid, in Experimental Allergic Contact Dermatitis. ACD, AEA, CBD, HaCaT, I-RTX, IL-6, MCP-2, TRPV1
21  2018 Cannabis sativa: A comprehensive ethnopharmacological review of a medicinal plant with a long history. 2-AG, AEA, CB1, D9-THC, MPNS
22  2018 Development of selective, fluorescent cannabinoid type 2 receptor ligands based on a 1,8-naphthyridin-2-(1H)-one-3-carboxamide scaffold. ---
23  2018 Effects of Cannabinoid Drugs on Aversive or Rewarding Drug-Associated Memory Extinction and Reconsolidation. 2-AG, CB1, eCB
24  2018 Effects of Cannabinoid Type 2 Receptor Agonist AM1241 on Morphine-Induced Antinociception, Acute and Chronic Tolerance, and Dependence in Mice. ---
25  2018 Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor. ---
26  2018 Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects. CB1, CNS, DRN, LC, NA
27  2017 Abnormalities in Dynamic Brain Activity Caused by Mild Traumatic Brain Injury Are Partially Rescued by the Cannabinoid Type-2 Receptor Inverse Agonist SMM-189. LFPs, mPFC, mTBI, PAC, SWR
28  2017 Cannabimimetic phytochemicals in the diet - an evolutionary link to food selection and metabolic stress adaptation? ECS
29  2017 Effects of coadministration of low dose cannabinoid type 2 receptor agonist and morphine on vanilloid receptor 1 expression in a rat model of cancer pain. DRG, TRPV1
30  2017 Highly selective CB2 receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice. CAT, COX-2, EtOH, GI, GU, IHC, SOD
31  2017 The cannabinoid beta-caryophyllene (BCP) induces neuritogenesis in PC12 cells by a cannabinoid-receptor-independent mechanism. BCP
32  2016 Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease. BCP, DA, i.p, PD, ROT, SNpc
33  2016 Low-Dose Cannabinoid Type 2 Receptor Agonist Attenuates Tolerance to Repeated Morphine Administration via Regulating mu-Opioid Receptor Expression in Walker 256 Tumor-Bearing Rats. DRG, i.t, MOR, mRNA
34  2016 Mild Traumatic Brain Injury Produces Neuron Loss That Can Be Rescued by Modulating Microglial Activation Using a CB2 Receptor Inverse Agonist. BLA, CREB, PARV
35  2016 Polypharmacological Properties and Therapeutic Potential of beta-Caryophyllene: A Dietary Phytocannabinoid of Pharmaceutical Promise. BCP, PPARs
36  2016 Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease. LPS, PD, TH
37  2015 A potential role for cannabinoid receptors in the therapeutic action of fenofibrate. CB1, PPARs
38  2015 An endocannabinoid system is present in the mouse olfactory epithelium but does not modulate olfaction. 2-AG, CB1
39  2015 The spinal anti-inflammatory mechanism of motor cortex stimulation: cause of success and refractoriness in neuropathic pain? DHSC, MCS
40  2014 Cannabinoid type 1 and type 2 receptor antagonists prevent attenuation of serotonin-induced reflex apneas by dronabinol in Sprague-Dawley rats. CB1, EMGgg, OSA
41  2014 Global fold of human cannabinoid type 2 receptor probed by solid-state 13C-, 15N-MAS NMR and molecular dynamics simulations. MAS, MD
42  2014 The genetic ablation or pharmacological inhibition of TRPV1 signalling is beneficial for the restoration of quiescent osteoclast activity in ovariectomized mice. TRPV1
43  2013 Activation of cannabinoid type 2 receptor by JWH133 protects heart against ischemia/reperfusion-induced apoptosis. AI, I/R
44  2013 Inhibitory effects of endocannabinoid on the action potential of pacemaker cells in sinoatrial nodes of rabbits. AEA, AP, APA, APD, CB1, L-NAME, NO, SAN, TEA
45  2013 Radiolabeling and in vitro /in vivo evaluation of N-(1-adamantyl)-8-methoxy-4-oxo-1-phenyl-1,4-dihydroquinoline-3-carboxamide as a PET probe for imaging cannabinoid type 2 receptor. ALS, BBB, PET
46  2011 Gut feelings about the endocannabinoid system. CB1
47  2010 Echinacea-induced cytosolic Ca2+ elevation in HEK293. 2-APB
48  2010 Microfluidic approach for fast labeling optimization and dose-on-demand implementation. SPE
49  2010 Radiosynthesis of novel carbon-11-labeled triaryl ligands for cannabinoid-type 2 receptor. ---
50  2009 The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. IR, MI, WT
51  2007 Self-assembling cannabinomimetics: supramolecular structures of N-alkyl amides. CMC
52  2006 Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. IL
53  2006 New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors. CB1
54  2005 The endocannabinoid system: a new approach to control cardiovascular disease. CB1, EC